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Abstract
In animal models and human cross-sectional studies, vitamin D deficiency has been associated with liver disease
progression. Vitamin D supplementation has been suggested as a treatment to prevent disease progression. We sought to
evaluate the role of vitamin D levels in predicting chronic liver disease development. We conducted a nested case-control
study of vitamin D levels in subjects with (cases) and without (controls) liver histologic progression or clinical
decompensation over the course of the HALT-C Trial. Vitamin D levels were measured at 4 points over 45 months. 129 cases
and 129 aged-matched controls were included. No difference in baseline vitamin D levels were found between cases and
controls. (44.8 ng/mL vs. 44.0 ng/mL, P=0.74). Vitamin D levels declined in cases and controls over time (P=0.0005),
however, there was no difference in the level of decline (P=0.37). Among study subjects with diabetes mellitius, baseline
vitamin D levels were higher in cases, 49.9 ng/mL, than controls, 36.3 ng/mL. (P=0.03) In addition, baseline vitamin D levels
were higher in black case subjects, 32.7 ng/mL, than in black control subjects, 25.2 ng/mL (P=0.08) No difference in vitamin
D levels was found between patients with and without progression of hepatitis C-associated liver disease over 4 years. Our
data do not suggest any role for vitamin D supplementation in patients with advanced chronic hepatitis C and raise the
possibility that higher vitamin D levels may be associated with disease progression.
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Introduction
Hepatic fibrosis results from wound healing following acute and
chronic liver injury. In response to chronic hepatic inflammation,
parenchymal cells release extracellular matrix proteins including
type I collagen, resulting in the progressive deposition of, and
accumulation of, fibrosis. Ultimately, fibrotic tissue can replace
hepatocytes and disrupt lobular architecture, the hallmark of
cirrhosis,which, inturn, results eventuallyinhepaticdysfunction.[1]
Emerging data suggest that vitamin D is an important
modulator of both the inflammatory response and wound healing.
[2,3] Vitamin D may modulate the inflammatory response and
subsequent fibrosis via inhibition of TNF-a, a cytokine that plays a
central role in the regulation of the immune response [4,5] and by
inhibiting the development of fibrosis directly through suppression
of TGF-b, a multifunctional cytokine that may influence fibrosis
progression [6].[7].[8].
The importance of vitamin D in immune modulation and
deposition of fibrosis may extend to the liver, which plays an
important role in vitamin D homeostasis. The liver is the site of the
conversion of vitamin D3 to 25-hydroxy-vitamin D (25-OH-
vitamin D) and may be a site of vitamin D storage. [9] In addition,
vitamin D receptors exist on hepatocytes and other hepatic
parenchymal cells, including hepatic stellate cells. As in the kidney,
vitamin D is postulated to play an antiinflammatory and
antifibrotic role in the liver via binding to promoters of target
genes, leading to down-regulation of TNF-a and TGF-b
production.
Cross-sectional population data suggest that vitamin D
deficiency is common in persons with advanced liver disease.
[10,11] For example, Fisher et al. [12] evaluated vitamin D levels
in 100 patients with liver disease, 51 with cirrhosis and 49 without
cirrhosis, including 38 patients with chronic hepatitis C. The
prevalence of vitamin D deficiency was significantly higher in
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p=0.0001). Moreover, vitamin D levels decreased with advancing
Child class; vitamin D levels were significantly lower in subjects
with Child class C (22.7 nmol/L) than in those with Child class A
(45.8 nmol/L, p,0.001). Such studies, however, are limited by
their cross-sectional nature. Thus, while an association between
vitamin D deficiency and advancing liver disease has been noted,
the potential that vitamin D deficiency could be a predictor for
progressive liver disease has not been explored.
Recently, vitamin D has been evaluated as a potential
immunomodulator of hepatitis C virus (HCV), and preliminary
data suggest that the addition of vitamin D to standard antiviral
therapy may improve treatment response rates. [13] This
observation lends further weight to the potential immunomodu-
latory role of vitamin D in liver disease.
The progression of hepatic fibrosis occurs over years, hamper-
ing the study of processes that affect fibrosis. On the other hand,
the Hepatitis C Antiviral Long-term Treatment against Cirrhosis
(HALT-C) Trial provided a unique opportunity to study fibrosis
longitudinally over several years. [14] The HALT-C Trial was a
10-clinical center randomized, controlled trial to evaluate the
benefit of long-term (3.5-years) peginterferon therapy in patients
with histologically advanced (Ishak fibrosis stage $3) but clinically
compensated chronic hepatitis C who had failed to respond
previously to antiviral therapy. While the HALT-C Trial was a
negative study, showing that such maintenance antiviral therapy
was ineffective, the trial’s study design, including sequential liver
biopsies spanning 4 years rendered the trial population ideally
suited for the study factors that might influence fibrosis
progression. Therefore, we conducted a nested case-control study
of vitamin D levels in subjects with and without liver histologic
progression or clinical decompensation over the course of the
HALT-C Trial.
Results
Baseline Characteristics of Cases and Controls
One hundred twenty-nine cases met the inclusion criteria and
129 aged matched controls were selected. (Table 1). Cases with
progression were defined (as the primary outcomes in the HALT-
C Trial) as subjects with Ishak fibrosis stage 3 or 4 who
experienced (1) progression of fibrosis over the study period,
defined by an increase in Ishak fibrosis score of $2 stages, (2) an
increase in the Child-Turcotte-Pugh (CTP) score to $7 on two
successive study visits (3 months apart), (3) hepatic decompensa-
tion, defined by the presence of ascites, hepatic encephalopathy,
variceal hemorrhage, spontaneous bacterial peritonitis, or (4)
death. Controls were subjects with stage 3 or 4 fibrosis who did not
experience any of the primary study endpoints by the end of 4-
years in the trial (a 24-week lead-in phase when all participants
received full-dose peginterferon alfa-2a and weight-based ribavirin
and a 3-K-year randomized phase of half-dose maintenance
peginterferon therapy or observation).
The mean age was 49.5 years in the cases and 50.0 years in the
controls, the mean BMI was 30.5 in the cases and 29.5 in the
controls (P=0.16), genotype 1 was predominant in both groups,
and the mean viral load was 6.4 and 6.5 log10 IU/ml in cases and
controls, respectively. Histologic Activity Index did not differ
significantly between the two groups (P=0.15). However, the cases
had a significantly higher baseline ALT levels than controls (136.4
versus 103.8, P=0.013). In addition, cases had more steatosis than
controls (p=0.002). 50.4% of control patients and 46.5% of case
patients received pegylated interferon during the HALT-C trial
(P=0.53).
To further ensure that our cases and controls were appropri-
ately selected we analyzed end of study levels of albumin,
prothrombin time and platelets. Cases had significantly lower
platelets than control patients (131.1 vs 180.7, p,0.0001) and
significantly lower albumin level (3.77 vs 4.06, p,0.0001) and
higher prothrombin times (1.09 vs 1.03, p,0.0001) suggesting that
cases were correctly classified as having progressive disease.
When evaluated by HALT-C treatment status (pegylated
interferon versus placebo) there was no difference in the
distribution of gender, ethnicity, age, BMI, steatosis, HAI, glucose,
HOMA-IR, ALT, genotype, average drinks per day, prevalence of
diabetes, albumin, platelet count, total bilirubin. Subjects who
received pegylated interferon had statistically lower baseline HCV
RNA log (6.19 IU/mL vs 6.42 IU/mlL, p=0.01).
Over the duration of the HALT-C Trial, 97.7% (n=126) of
cases had a $2-point increase in Ishak fibrosis score, and 17.1%
(n=22) had an increase in CTP score to $7. Encephalopathy
developed in 6.2% (n=8) of cases, ascites in 7.8% (n=10), variceal
hemorrhage in 2.3% (n=3), and spontaneous bacterial peritonitis
in 1.6% (n=2) of patients. The death rate among cases was 5.4%
(n=7) and 3.1% among controls (n=4), which was not statistically
different (p=0.54).
Factors Associated with Vitamin D Deficiency
Two vitamin D measurements were made in this study, vitamin
D3 and vitamin D2 levels. Vitamin D3 levels reflect endogenous
vitamin D while vitamin D2 levels reflect exogenous vitamin D (or
vitamin from supplements). Total vitamin D is the sum of the
vitamin D2 and Vitamin D3 levels.
Vitamin D levels have been shown to vary by latitude and
season with higher vitamin D levels found in summer months and
at latitudes closer to the equator. [15] Thus, we evaluated whether
our cases and controls differed by latitude of HALT-C site and
season during which blood was drawn.
We found no difference in the months of blood draws between
cases and controls (P=0.53) or in the season when evaluating
winter (October to April) compared to summer (May to
September) (P=0.44). In addition, there was no difference in the
location of clinical center between cases and controls. In the
control group 27.8% of subjects and 27.1% of subjects in the case
group came from latitudes of 35 degrees or less compared to
72.2% at latitudes greater than or equal to 35 degrees in the
controls and 72.9% of cases. (P=0.91)
In addition, we evaluated the difference in vitamin D levels
based on HALT-C treatment status. No significant difference in
vitamin D level was seen between subjects who received pegylated
interferon and those who received placebo (34.7 mg/dL vs
35.7 mg/dl, p=0.61). When further divided by cases and controls
there was again no difference between subjects who received
pegylated interferon and those who received placebo. Among
cases who received pegylated interferon, mean vitamin D level was
34.7 mg/dL compared to 36.4 mg/dL in the placebo group
(p=0.52). Among controls who received pegylated interferon
mean vitamin D level was 34.7 mg/dL compared to 35.0 mg/dL
in the pacebo group p=093).
A low vitamin D level was associated independently with black
race (P,0.0001). (Table 2) Vitamin D levels were also significantly
associated with the month of blood draw (P,0.0001). These
remained significant when adjusted for the age, gender, BMI,
HCV RNA level, diabetes, HAI, race, site of draw, month of draw
and genotype. Clinical trial site was associated with vitamin D
level with sites at latitudes of 35 degrees or below having
significantly higher vitamin D levels than those above 35 degrees
(40.1 mg/dL vs 46.0 mg/dL, P=0.02) but was not significant
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also found to be higher in patients with genotype 1 compared to
non-genotype 1 patients (+10.75 mg/dL, p=0.04) but is limited
by only 15 patients being non-genotype 1. This association was not
significant on multivariate analysis (p=0.09) Vitamin D levels
were not related to age, gender, BMI, HCV RNA level, presence
of diabetes mellitus, Histologic Activity Index, or ALT when
multivariate analysis was performed.
Are Vitamin D Levels Predictive of the Progression of
Chronic Liver Disease?
Vitamin D levels were assessed at the time of HALT-C Trial
screening, randomization to peginterferon or placebo (week 24), at
month 27, and month 45 (Table 3). Baseline total vitamin D levels
were 44.8 ng/mL in the cases and 44.0 ng/mL in the controls
(P=0.74). Levels in both groups declined over the study period,
falling to 44.4 ng/mL in cases and in 44.2 ng/mL controls at the
time of randomization (P=0.91), to 40.5 ng/mL in cases and
39.2 ng/mL in controls at month 27 (P=0.59), and to 38.8 ng/
mL in cases and 40.9 ng/mL in controls at month 45 (P=0.32).
While vitamin D levels declined significantly in both cases and
controls over time (P=0.0011), no difference emerged in the level
of the decline between the case and control groups (25.6 ng/mL
versus 23.3 ng/mL respectively, P=0.77). In addition, the levels
of vitamin D2 (exogenous vitamin D derived from supplement use)
and vitamin D3 (endogenous) did not differ between cases and
controls at any time point during the study.
The prevalence of vitamin D deficiency, defined as is standard
by a vitamin D level #30 ng/ml, was indistinguishable between
cases, 24.6%, and controls, 23.8% (P=0.88). Similarly, extreme
Table 1. Baseline characteristics of the cases and controls in the nested analysis.
Case N (%) Controls N (%) P Value
N 129 129
Male (%) 89 (69.0) 100 (77.5) 0.16
Female (%) 40 (31.0) 29 (22.5)
Non-Hispanic White (%) 99 (76.7) 91 (70.5) 0.34
Black (%) 19 (14.7) 27 (20.9)
Hispanic (%) 8 (6.2) 5 (3.9)
Other (%) 3 (2.3) 6 (4.7)
Mean Age (6 SD) 49.566.5 50.067.3 0.54
Mean BMI (6 SD) 30.565.4 29.565.0 0.16
BMI Profile (%) 0.19
- ,18.5 0(0) 1(0.78%)
- 18.5–24.9 14(10.85%) 20(15.50%)
- 25–29.9 52(40.31%) 62(48.06%)
- 30–34.9 48(37.21%) 31(24.03%)
- 35–39.9 10(7.75%) 8(6.20%)
- .40 5(3.88%) 7(5.43%)
HCV Genotype 1 119(92.3) 124 (96.1) 0.28
HCV Genotype other 10 (7.8) 5 (3.9)
HCV RNA Log10 IU/ml (6 SD) 6.460.5 6.560.5 0.33
Mean Ishak Histologic Activity Index (6 SD) 7.462.1 7.061.9 0.15
ALT (U/L) 136.46125.7 103.8677.6 0.013
Steatosis (%) 0.002
0 20(15.50%) 28(21.71%)
1 38(29.46%) 62(48.06%)
2 46(35.66%) 28(21.71%)
3 21(16.28%) 10(7.75%)
4 4(3.10%) 1(0.78%)
Mean Glucose mg/dL (+/2SD) 113646 105635 0.12
Mean Insulin (+/2SD) 54.6639.7 43.1645.4 0.06
Mean HOMA-IR 16.8616.6 12.6617.7 0.09
Average Number of drinks per year (6 SD) 683.761056.2 641.26875.0 0.73
Average grams of ETOH per day (6 SD) 22.5634.7 21.1628.7 0.73
Diabetes (%) 27 (20.9) 16 (12.4) 0.09
Pegylated Interferon Treatment 60 (46.5) 65 (50.4) 0.53
Blood drawn during winter months (out of 1023 draws) 284 (48.8) 298 (51.2) 0.44
doi:10.1371/journal.pone.0027144.t001
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was found in 7.1% of cases and 10.4% of controls (P=0.38).
We suspected that while vitamin D levels may not be
significantly different in our cohort as a whole, vitamin D
deficiency may be higher in cases and controls in certain
subgroups, diabetic subjects and black subjects, at higher risk for
vitamin D deficiency. We found that in subjects with an
established diagnoses of diabetes mellitius or an elevated fasting
glucose .126, baseline vitamin D levels were higher in cases,
47.9 ng/mL, than controls, 36.3 ng/mL (P=0.03) (Table 4 and
5). In addition, baseline vitamin D levels were higher in black
subjects who had progressive liver disease, 32.7 ng/mL, than in
black control subjects, 25.2 ng/mL (P=0.08) (Table 6). These
findings suggest, contrary to our belief, that increased serum
vitamin D levels may be associated with a risk of liver-disease
progression in specific groups with other risk factors.
Vitamin D Supplement Use
The self-reported use of vitamin D supplements was not
available from the HALT-C study. However, vitamin D
supplement use was directly measured by assaying for vitamin
D2 levels. Over the course of the four year study 118 subjects did
not have a detectable vitamin D2 level at any of the four time
points indicating no supplement use with the remainder having a
detectable vitamin D2 level at at least one time point. There was
no significant difference in this distribution between cases and
controls. (P=0.14).
We analyzed the mean total vitamin D levels, vitamin D3 and
vitamin D2 levels in those subjects with detectable vitamin D2
levels on all four occasions to determine if supplement use was
greater in control patients and could account for a lack of
progression of chronic liver disease (n=28). We noted that at
baseline cases had significantly higher vitamin D3 levels (46.3 mg/
dL vs 32.4 mg/dL, P=0.03) and total vitamin D levels (60.0 mg/
dL vs 43.3 mg/dL, P=0.02) when compared to control patients.
(Table 7) Vitamin D2 levels, indicative of supplement use, had a
trend toward higher levels in cases compared to controls
(13.7 mg/dL vs 10.9 mg/dL, P=0.28) although this did not
reach statistical significance. We did not find, however, the
supplement use or higher total vitamin D levels were associated
with improved outcomes and our findings suggest that higher
vitamin D levels may be associated with progression of liver
disease.
Further, we analyzed the baseline vitamin D levels in patients
who were taking vitamin D supplements at the time of enrollment
(N=77). We found that total vitamin D levels were significantly
higher in the cases (53.6 mg/dL) when compared to controls
(44.7 mg/dL, P=0.04). Cases had a non-significant increase in
both vitamin D2 (10.5 mg/dL vs. 8.1 mg/dL, P=0.10) and
vitamin D3 levels (42.5 mg/dL vs. 36.6 mg/dL, P=0.16) when
compared to controls.
Discussion
In this study, we had the opportunity to evaluate longitudinally
the impact of vitamin D levels on the progression of chronic liver
disease. Our nested case control study suggests that vitamin D
levels do not influence the progression of chronic liver disease. We
found no difference in mean vitamin D levels in patients with and
without progressive chronic liver disease during any point over 45
months. Vitamin D levels declined over time in both groups
consistent with the known effect of aging on vitamin D levels but
persons with progression of liver disease did not experience a
greater decline than persons without disease progression. [16] The
existing literature contains conflicting evidence on the relationship
between vitamin D and chronic liver disease. Our findings are
supported by several studies in the literature evaluating vitamin D
levels in chronic viral liver disease. Duarte et al evaluated 100
persons with chronic hepatitis C and found no difference in mean
vitamin D levels in those with and without cirrhosis. Their levels of
vitamin D, 46.6 ng/mL in non-cirrhotic persons and 45.6 ng/mL
in cirrhotic patients (P=NS), were similar to the levels in our
study. [17] Gallego-Rojo et al found similar levels with Child’s
Class A cirrhotic patients having a non-significant increase in
vitamin D when compared to healthy controls (48.1 ng/mL vs.
45.5 ng/mL, respectively). [18] However, in several studies
decreasing vitamin D levels have been associated with progression
of chronic liver disease. [10,12,19,20]. However, these studies
have several important limitations in their design that may explain
the different findings. First, these studies are universally cross
Table 2. Factors associated with vitamin D level (univariate).
Baseline Characteristics P Value
HCV RNA level 0.45
BMI 0.73
Age 0.06
Gender 0.89
ALT U/L 0.61
Diabetes mellitus 0.81
Average alcoholic drinks per year 0.13
Race 0.0001
HCV Genotype 0.04
Diabetes or blood sugar .126 mg/dL 0.73
Month of blood draw ,0.0001
Site of blood draw 0.006
doi:10.1371/journal.pone.0027144.t002
Table 3. Mean vitamin D (ng/mL) levels in cases and controls.
Cases (n=129) Control (n=129) P value
Total D2 D3 Total D2 D3 Total D2 D3
Month 0 (Screening) 44.8619.4 3.066.1 41.6618.3 44.0619.7 2.564.7 41.4619.9 0.74 0.47 0.94
Week 24 (Randomization) 44.4619.8 3.165.8 41.4620.2 44.2619.7 2.264.3 41.2619.0 0.91 0.17 0.92
Month 27 40.5617.3 3.265.9 37.6617.4 39.2620.7 2.364.3 35.6617.6 0.59 0.15 0.38
Month 45 38.8618.4 3.265.6 35.6618.3 40.9613.8 3.465.7 37.6614.1 0.32 0.87 0.33
doi:10.1371/journal.pone.0027144.t003
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and liver disease at only a single point in time and therefore are
unable to assess changes in vitamin D temporally with the
progression of liver disease. [10,12,19,20]. In addition, control
subjects have in large part consisted of healthy controls
introducing potentially confounders. Vitamin D levels have been
found to be decreased in persons with a number of chronic
diseases including hypertension, diabetes mellitus, nephritic
syndrome and chronic kidney disease and further vitamin D level
is considered an excellent marker of overall general health. [21,22]
Thus, vitamin D deficiency may be the result of the chronic
disease state rather than specifically the result of chronic liver
disease which would not be highlighted by the use of healthy
controls. Our study design, however, allows for controlling for the
presence of chronic disease by choosing controls with chronic liver
disease. By controlling for chronic disease we found that no
difference was apparent in vitamin D levels.
Several advantages exist in the design of our study when
compared to previously published works on vitamin D in chronic
liver disease. First, our study was a nested case control rather than
a traditional case control study. Nested case control studies have a
distinct advantage from traditional case control studies because
both cases and controls are chosen from the same, well-defined
source population, in this study from the HALT-C study
population where all patients had chronic hepatitis C infection
with chronic liver disease. This is in contrast to other recently
published works of cross-sectional case control studies where
controls were uninfected healthy subjects. [20] Further, the
traditional disadvantage of nested case control studies, which the
cases and controls differ due to a higher death rate or loss to
follow-up in the controls was not seen in HALT-C where no
patients were lost to follow-up and only 21 deaths occurred.
In this study we also found that in specific subgroups, diabetic
patients and black patients, cases had higher vitamin D levels than
Table 4. Baseline characteristics of diabetic cases and controls in the nested analysis.
Case N (%) Controls N (%) P Value
N2 7 1 6
Male (%) 20(74%) 15(94%) 0.11
Female (%) 7(26%) 1(6%)
Non-Hispanic White (%) 20(74.07%) 6(37.50%) 0.04
Black (%) 5(18.52%) 8(50%)
Hispanic (%) 1(3.70%) 2(12.50%)
Other (%) 1(3.70%) 0(0%)
Mean Age (6 SD) 5267.0 5266.4 0.88
BMI Profile (%) 0.55
- ,24.9 2(7.41%) 4(25%)
- 25–29.9 11(40.74%) 7(43.75%)
- 30–34.9 9(33.33%) 3(18.75%)
- 35–39.9 2(7.41%) 1(6.25)
- .40 3(11.11) 1(6.25)
Mean Ishak Histologic Activity Index (6 SD) 6.4461.65 7.2561.61 0.12
ALT (U/L) 103.7667.9 84.1651.7 0.33
Steatosis (%)
0 6(22.22%) 6(37.50%) 0.34
1 9(33.33%) 8(50%)
2 7(25.93%) 1(6.25%)
3 4(14.81%) 1(6.25%)
4 1(3.70%) 0(0%)
Average Number of drinks per year (6 SD) 6536758 6526823 0.99
doi:10.1371/journal.pone.0027144.t004
Table 5. Mean baseline vitamin D (ng/mL) levels by in
patients by diabetes status.
Cases Controls P value
Diabetes 47.9619.4 36.3616.0 P=0.03
Non-DM 43.7619.4 45.4620.1 P=0.53
doi:10.1371/journal.pone.0027144.t005
Table 6. Mean baseline vitamin D (ng/mL) levels by race.
Cases Controls P Value
African Americans 32.7615.8 25.2612.4 0.08
White 47.2619.7 49.7618.5 0.36
Hispanic 48.8613.6 53.8615.2 0.54
Other 32.1617.1 32.065.6 0.99
doi:10.1371/journal.pone.0027144.t006
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harmful in these subgroups. Diabetic and black patients may be
more susceptible to fibrosis progression, a progression that may be
exacerbated by elevated levels of vitamin D. [20,23,24,25] While
our study was not designed to evaluate the effect of vitamin D on
fibrosis in these specific subgroups further study the suggestion of
an association between elevated levels of vitamin D and
accelerated disease progression in these groups warrants further
evaluation.
Our study has several important limitations. First, in three
quarters of our study subjects, the mean vitamin D levels were
normal. This high proportion of normal vitamin D levels may be
the result of the high supplement use among this group. Over the
course of this study 140 subjects (54.7%) had detectable vitamin
D2 levels, evidence of supplement use. In addition, subjects willing
to participate in this rigorous long term trial may be highly
motivated and have increased outdoor exercise and sun exposure
leading to higher vitamin D levels. If the benefit of vitamin D were
limited to vitamin D-deficient subjects, our study would have been
underpowered to detect such an effect of vitamin D. On the other
hand, in the two subgroups that did show a difference in vitamin D
levels between cases and control, diabetics and black patients,
vitamin D levels were higher in cases with histologic and/or
clinical progression than in stable controls. Furthermore, in black
subjects, mean vitamin D levels were in the deficiency range (mean
28.6 ng/mL); yet, vitamin D levels were higher in cases and then
in controls.
In addition, our study is limited by its evaluation of only patients
in the HALT-C study. The HALT-C study was limited to subjects
who did not achieve sustained virologic response (SVR) to
standard therapy. Low SVR rates have been associated with low
vitamin D levels and suggest that at interaction between normal or
high vitamin D levels may impact SVR. The patients in HALT-C,
non-responders to therapy, may be a select group who do not
benefit from normal or increased vitamin D levels and whose
disease progression is not impacted by vitamin D.
In addition, in our study, we limited our evaluation to patients
with Ishak fibrosis stage 3–4. Potentially, the benefits of vitamin D
elevation (and supplementation) are negligible once this degree of
fibrosis has occurred; our study group would not have revealed
whether vitamin D may be beneficial in patients with no or early-
stage fibrosis. On the contrary, by focusing on patients with stage
3–4 hepatic fibrosis, we were targeting patients with a high risk of
disease progression, a group in which we would have expected to
see the greatest potential benefit. In addition, we evaluated only
patients with hepatitis C-induced liver disease and did not evaluate
the role of vitamin D in other forms of chronic liver disease.
Potentially, the impact of vitamin D levels in other types of chronic
liver disease might be different.
Finally, while the HALT-C study had more than 4 years of
follow-up this may still be insufficient follow-up time to adequately
assess our desired outcomes. As was recently seen in an extended
cohort of HALT-C, maintenance interferon therapy was associ-
ated with a reduced risk of HCC in cirrhotic patients. [26] Thus,
vitamin D may be a predictor of longer term outcomes that cannot
be assessed in the original HALT-C study.
In conclusion, we found no difference in vitamin D levels
between patients with and without progression of hepatitis C-
associated chronic liver disease over the course of nearly 4 years.
Although we have not conducted a randomized trial of vitamin-D
supplementation, our data do not suggest any role for vitamin D
supplementation in patients with histologically advanced chronic
hepatitis C and even raise the possibility that vitamin D
supplementation may be harmful. Of course, vitamin D
supplementation has been linked with a myriad of other health
benefits, and our data are insufficient to support withholding
vitamin D from these patients. On the side of caution, however,
further study is needed in to evaluate the role of vitamin D
supplementation in patients with chronic liver disease who are
diabetic or black.
Methods
This ancillary study was approved by the Partners Human
Research Committee. The HALT-C Trial was approved by
institutional review boards at each of the participating sites, and all
study subjects provided written informed consent. Participating
sites included University of Massachusetts Medical School,
Worcester, MA; University of Connecticut Health Center, Farm-
ington, CT; Saint Louis University, Saint Louis, MO, Partners
Healthcare, Boston, MA; University of Colorado Health Sciences,
Aurora, CO; University of California, Irvine, Ivine, CA; Long
Beach VAMC Research Health Care Group, Long Beach,
California; University of Texas Southwestern Medical Center,
Dallas, TX; University of Southern California Health Sciences
Campus, Los Angeles, CA; University of Michigan Medical
School, Ann Arbor, MI; Virginia Commonwealth University,
Richmond, VA; National Institute of Diabetes and Digestive and
Kidney Diseases National Institutes of Health, Bethesda, MD.
Study Design
This was a case-control study to evaluate the association of
serum 25-OH-vitamin D levels with fibrosis progression. Cases
with progression were defined (as the primary outcomes in the
HALT-C Trial) as subjects with Ishak fibrosis stage 3 or 4 who
experienced (1) progression of fibrosis over the study period,
defined by an increase in Ishak fibrosis score of $2 stages, (2) an
increase in the Child-Turcotte-Pugh (CTP) score to $7 on two
Table 7. Analysis of vitamin D levels in patients with detectable vitamin D2 at all time points.
Cases (n=16) Control (n=12) P value
Total D2 D3 Total D2 D3 Total D2 D3
Month 0 (Screening) 60.0615.9 13.766.6 46.3615.7 43.3619.0 10.966.6 32.4617.2 0.02 0.28 0.03
Week 24
(Randomization)
44.5614.0 11.865.7 32.7612.2 50.8615.2 9.565.7 41.3616.4 0.27 0.30 0.12
Month 27 41.6612.9 12.365.3 30.7610.7 39.067.9 9.463.7 29.668.5 0.54 0.12 0.77
Month 45 41.6614.6 11.966.2 29.7612.7 43.3613.8 10.765.6 32.7613.7 0.75 0.60 0.57
This is publication #59 of the HALT-C Trial.
doi:10.1371/journal.pone.0027144.t007
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tion, defined by the presence of ascites, hepatic encephalopathy,
variceal hemorrhage, spontaneous bacterial peritonitis, or (4)
death. Controls were subjects with stage 3 or 4 fibrosis who did not
experience any of the primary study endpoints by the end of 4-
years in the trial (a 24-week lead-in phase when all participants
received full-dose peginterferon alfa-2a and weight-based ribavirin
and a 3-K-year randomized phase of half-dose maintenance
peginterferon therapy or observation). We chose to expand our
primary endpoint beyond fibrosis progression alone to limit the
impact of the sampling variability of needle-liver biopsy as well as
to include clinically significant outcomes. Controls and cases were
matched for age (age less than 49 years of age or age equal to or
greater than 49 years of age) Because hepatocellular carcinoma
(HCC) may have independent effects on vitamin D homeostasis,
we excluded patients in whom HCC developed. [27]
Inclusion Critieria
To be included as a case or a control in the nested case-control
study, HALT-C Trial participants had to have (1) liver
histopathology available at study entry and study cessation
(baseline and 4 years [biopsies were done at baseline, year 2 and
year 4]), (2) stored serum available for 25-OH-vitamin D assay,
and (3) Ishak fibrosis stage 3 or 4 at study entry. Subjects with
Ishak Fibrosis stage 5 or 6 at study entry, absence of serial liver
biopsies, and those in whom HCC developed during the study
period were excluded. Two hundred fifty-eight subjects from the
HALT-C Trial met these inclusion criteria including 129 cases
and 129 controls.
Endpoints
The primary endpoint was the mean vitamin D level at study
entry; secondary endpoints were vitamin D levels at randomiza-
tion (trial-week 24), month 27, and month 45. –Total 25-OH-
Vitamin D was calculated from the sum of 25-OH vitamin D3
(endogenously produced vitamin D) and 25-OH-vitamin D2
(derived from supplements). Serum samples were aliquoted and
frozen immediately at 270uC at each of the 10 clinical centers,
then shipped on dry ice and stored at a central contract repository
site. For the measurement of vitamin D levels deuterated stable
isotope [d3-25-hydroxyvitamin D] was added to a 200 uL serum
specimen as an internal standard. The specimen was then
deproteinated by acetonitrile precipitation. 25-hydroxyvitamin
D2, 25-hydroxyvitamin D3, and internal standard in the organic
supernate were purified by a liquid chromatography system.
Purified hydroxyvitamin D2, 25-hydroxyvitamin D3, and internal
standard are ionized at atmospheric pressure and injected into a
tandem mass spectrometer and quantified relative to calibrators
prepared in charcoal-stripped human serum. The limit of
quantitation for 25-hydroxyvitamin D2 is 2 ng/mL [CV=15%]
and for 25-hydroxyvitamin D3 is 3 ng/mL [CV=25%]. The
between-run CV for a quality control serum containing a total
vitamin D concentration of 23 ng/mL is 7.5%. Storage time, up to
24 years, has shown to have no effect on vitamin D levels in stored
serum. [28]
Statistical Analysis
We evaluated serum vitamin D levels in cases and controls as
continuous variables. Baseline was defined as time of randomiza-
tion. For those patients whose information was missing at
randomization, information at screening was used as baseline.
The cases and controls were weakly matched by age only. As a
result, the correlation between case and control were very weak
and the two groups can be considered independent. Student’s t test
or Wilcoxon rank sum test was used as appropriate. Fisher’s exact
test or Chi-square test was used for bivariate analyses of
categorical variables whenever appropriate. In addition, we
evaluated serum 25-OH-vitamin D levels as categorical variables
(binary: deficient and normal value as well as in quartiles) with the
chi square test to create an odds ratio for the progression of fibrosis
based on vitamin D levels. We performed multivariate modeling to
evaluate the impact of vitamin D levels as well as other known
variables that influence fibrosis (age, estimated duration of HCV
infection, body mass index [BMI], diabetes mellitus, hypertension,
alcohol use) on fibrosis progression. In addition, we performed a
linear regression analysis to evaluate the impact of vitamin D levels
on HCV RNA levels. With a sample size of 129 subjects per study
arm, we had an 80% power to detect a mean difference of 0.3
times the standard deviation of the mean between groups at the
5% level of significance. Statistical analysis was performed with
SAS software (SAS 9.1.3 Cary, NC).
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